About the Company
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NVAX News
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery
With the pandemic largely in the rear-view mirror, vaccine maker Novavax has seen shares fall. Yet, analysts have high hopes ...
Analysis finds positive risk-benefit for Novavax COVID vaccine
A drop in overall infections, hospitalizations, and deaths outweighed the risk from rare reports of myocarditis or ...
What's Going On With Novavax Stock Today?
Novavax Inc (NASDAQ:NVAX) shares are trading higher. The company on Thursday reached a settlement for its 2021 vaccine ...
Why Is COVID-19 Vaccine Maker Novavax Stock Plunging On Wednesday?
Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2023 revenues of $291 million, down from $357 million a year ago, missing ...
Is Novavax a Buy Now?
Novavax (NASDAQ: NVAX) has taken investors on a roller coaster ... are the views and opinions of the author and do not ...
Novavax, Inc. (NASDAQ:NVAX) Q4 2023 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q4 2023 Earnings Call Transcript February 28, 2024 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.44 EPS, expectations were $-0.49. NVAX isn't one ...
Novavax: Q4 Earnings Snapshot
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Wednesday reported a loss of $178.4 million in its fourth quarter. On a per-share basis, the Gaithersburg, Maryland ...
Novavax, Inc. (NVAX) Q4 2023 Earnings Call Transcript
Good morning and welcome to Novavax Fourth Quarter 2023 Financial Results and Operational Highlights Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After ...
Loading the latest forecasts...